NV5 Appoints Kevin Wedman to Lead ENERGY 2021 Initiative
HOLLYWOOD, Fla., Jan. 03, 2019 (GLOBE NEWSWIRE) — NV5 Global, Inc. (Nasdaq: NVEE) (“NV5” or the “Company”), a professional engineering […]
Exela Technologies Acquires Healthcare Asset Adding Over $20 million of Annual Revenue
Transaction expected to contribute total revenue of over $170 million over the next seven years Exela’s Healthcare industry 2019 revenue […]
Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, […]
Minnesota State Bar Association Signs Agreement for December 2018 launch of Identillect’s Delivery Trust®
Minnesota State Bar Association partnering with Identillect Technologies as email security provider for members IRVINE, Calif., Jan. 03, 2019 (GLOBE […]
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased […]
Inovalon Announces Charitable Initiatives for 2018
Inovalon Drives Meaningful Impact through Charitable Giving Programs Serving Local and National Organizations BOWIE, Md., Jan. 03, 2019 (GLOBE NEWSWIRE) […]
Atara Biotherapeutics Announces Planned Chief Executive Officer Transition
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell […]
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, […]
Pacira Reports Preliminary 2018 Net EXPAREL® Sales of $331 Million
EXPAREL sales exceed upper end of guidance with expanding support from physicians, payers, and patients PARSIPPANY, N.J., Jan. 03, 2019 […]
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
WP1732 now second lead drug demonstrating enhanced activity in combination with immune checkpoint blockade antibodies HOUSTON, Jan. 03, 2019 (GLOBE […]
